Shifting from targeted therapies to personalised treatment in chordoma
Lancet Oncol
.
2020 Dec;21(12):e547.
doi: 10.1016/S1470-2045(20)30684-7.
Authors
Quintino Giorgio D'Alessandris
1
,
Giuseppe Maria Della Pepa
2
,
Martina Offi
1
,
Roberto Pallini
1
,
Alessandro Olivi
1
Affiliations
1
Department of Neurosurgery, Fondazione Policlinico Universitario "A Gemelli" IRCCS, Universitá Cattolica del Sacro Cuore, Rome 00168, Italy.
2
Department of Neurosurgery, Fondazione Policlinico Universitario "A Gemelli" IRCCS, Universitá Cattolica del Sacro Cuore, Rome 00168, Italy. Electronic address: giuseppemaria.dellapepa@policlinicogemelli.it.
PMID:
33271104
DOI:
10.1016/S1470-2045(20)30684-7
No abstract available
Publication types
Letter
Comment
MeSH terms
Chordoma*
Humans
Molecular Targeted Therapy
Precision Medicine
Pyridines / therapeutic use
Substances
Pyridines
apatinib